Research progress on probiotics and prebiotics in the treatment of nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is estimated to affect approximately 30% of the global population, making it a primary cause of chronic liver disease. The onset and progression of this condition are intricately linked to the intestinal microbiota. Probiotics and prebiotics, by modulating the gut microbiota, can slow down the disease progression in patients, thereby offering novel therapeutic targets for the clinical treatment of NAFLD. This article delves into the mechanistic research and clinical advancements in the understanding and use of probiotics and prebiotics in ameliorating NAFLD. Furthermore, it anticipates the future trajectory of probiotics and prebiotics in treating this condition, aiming to serve as a reference for further in-depth research on these beneficial microorganisms.